• Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America
• The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death
• In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone
• Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.